Develops cell therapies intended to help donor cells coexist with patients’ immune systems, for blood cancer treatment and potentially organ transplantation.
10-K for FY2024, filed Apr 7, 2026We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary…View ↗
The unique advantage of Cell Source technology lies in the ability to induce sustained tolerance of transplanted cells (or organs) by the…View ↗
Organ failure and transplantation. A variety of conditions can be treated by the transplantation of vital organs. However, transplantation…View ↗
No revenue reported yet.
10-K, filed Mar 13, 2015
The company plans to focus initial market entry on influential transplant centers; it also identifies centers that provide CAR-T treatments as a potential market.
10-K for FY2024, filed Apr 7, 2026
Loading...